Advanced in Squamous Cell Lung Carcinoma

Charles Dayen

Saint-quentin-le-verger, FR 
Advanced in Squamous Cell Lung Carcinoma
Saint-quentin-le-verger, FR 
OverviewLocationsClinical Research

Overview

Charles Dayen practices in Saint-quentin-le-verger, France. Mr. Dayen is rated as an Advanced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Squamous Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Squamous Cell Lung Carcinoma.

Gender
Male

Locations

Saint-quentin-le-verger, 02321, France
Other Locations
Amiens, France
Chauny, France
Lyon, France
10, Rue De La Grange Batelière, Paris, 75009, France
CHI Créteil
Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
View 1 Less Clinical Trial

27 Total Publications

Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
Journal: Frontiers in oncology
Published: March 31, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dayen's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile